跳至主要内容
临床试验/NCT02654158
NCT02654158已完成不适用

Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection

Guangzhou Yipinhong Pharmaceutical CO.,LTD1 个研究点 分布在 1 个国家目标入组 2,400 人开始时间: 2013年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
2,400
试验地点
1
主要终点
Duration of cold symptoms

研究概览

简要总结

Phase IV trial,Single-arm, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with acute upper respiratory infection

详细描述

Low-dose group of Fuganlin Oral Liquid:dosage from 5 to 10 ml;

High-dose group of Fuganlin Oral Liquid:dosage from 10 to 20 ml;

Treatment for 1 week.Patients who were recovered within 1 week can withdrawal at any time.

Research purpose:

  1. Evaluate the safety and efficacy of Fuganlin oral Liquid when expanding the designated indications(Qi deficiency wind-heat syndrome to wind-heat syndrome) .
  2. Explore the relationship between elevated white blood cells and efficacy, age and efficacy, dose and efficacy,While treating with Fuganlin oral Liquid in children with acute respiratory infection.
  3. Observe the antiviral and immunomodulatory effects of Fuganlin oral Liquid.
  4. Provide data to support the clinical medicine guidelines and labels amendment of Fuganlin oral Liquid.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
1 Year 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed as acute upper respiratory infection.
  • Patients with acute upper respiratory infection diagnosed as Tradition Chinese Medicine syndrome qi deficiency wind-heat.
  • Patients aged 1 to 12 years old.
  • Parents or guardians agreed to participate this study and signed the informed consent.

排除标准

  • Patients whose total numbers of white blood cells around above1.3ULN.
  • Patients diagnosed as suppurative tonsillitis, otitis media, bronchitis and other airway.
  • Patients allergic to the test drug.
  • Serious cardiovascular, liver,kidney and other primary systemic diseases.
  • Patients should not be included in group according to investigator's evaluation.

研究组 & 干预措施

Low-dose of Fuganlin Oral Liquid

oral

less than 1 years old: 5mL each time and three times a day

1~3 years old: 10mL each time and three times a day

4~6 years old: 10mL each time and four times a day

7~12 years old: 10mL each time and five times a day

干预措施: Low-dose of Fuganlin Oral Liquid (Drug)

High-dose of Fuganlin Oral Liquid

oral

less than 1 years old: 10mL each time and three times a day

1~3 years old: 20mL each time and three times a day

4~6 years old: 20mL each time and four times a day

7~12 years old: 20mL each time and five times a day

干预措施: High-dose of Fuganlin Oral Liquid (Drug)

结局指标

主要结局

Duration of cold symptoms

时间窗: Defined as the time from the onset of the cold to the time achieve a cold cure standard,time average 1 to 7 days

Cold diagnostic criteria: 1. Nasal congestion, runny nose, sneezing, itchy throat, or pain, cough 2. The chills, fever, no sweat or less sweat, headache, limb sour 3. The total numbers of normal or low white blood cells, neutropenia, relative increase in lymphocytes. Cold cure criteria: 1. Fever, aversion to wind individual symptoms disappeared 2. Nasal congestion, runny nose, sore throat, cough individual symptoms disappeared

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验